FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308378507> ?p ?o ?g. }

• W4308378507 abstract "<h3>Background</h3> Despite the remarkable success of immune modulating cancer therapies, the majority of patients does not benefit from the currently available therapies. Therefore, there is a high need for the identification of novel therapies targeting cancer-induced immunosuppression. The membrane-bound protein neuropilin-1 (NRP1) is a molecule with diverse functions and interaction partners that has been shown to contribute to tumor cell migration and survival as well as neoangiogenesis. Furthermore, NRP1 contributes to the suppressive capacity of immune cells like e.g. tumor associated macrophages and regulatory T cells. As the different functions of NRP1 are mediated by multiple domains of NRP1, there is a conceptual advantage to downregulate the expression of the whole protein over the functional or steric blockade of individual domains e.g. by monoclonal antibodies. <h3>Methods</h3> We used our in-house Oligofyer™ bioinformatics system to design human and mouse Nrp1-specific antisense oligonucleotides (ASOs). The ASOs were modified in the flanks with locked nucleic acids to increase stability and affinity to the target RNA. RNA knockdown efficacy in vitro was investigated in different cells without the use of a transfection reagent. We furthermore investigated the anti-tumor activity of selected mouse Nrp1-specific ASOs in different syngeneic mouse tumor models after systemic administration of unformulated ASOs. In vivo target knockdown in different cell types was investigated by flow cytometry. <h3>Results</h3> Treatment of different cell types with LNA-modified ASOs in vitro led to downregulation of NRP1 mRNA as well as protein expression by >85%. Systemic treatment of immune-competent tumor bearing mice with mouse Nrp1-specific ASOs without the use of a delivery reagent strongly delayed tumor growth or completely eradicated tumors. Furthermore, long-term anti-tumor immunity has been observed in immune-competent responder mice after re-challenge with tumor cells. The anti-tumor effects were almost completely absent in immune-compromised NSG mice. <h3>Conclusions</h3> Our encouraging results indicate that downregulation of NRP1 with LNA-modified ASOs has the potential to become a promising treatment option for patients in the future. Currently, further studies are performed to investigate therapeutic activity in additional tumor models, combination therapies as well as to fully elucidate the mechanisms that underlie the observed anti-tumor efficacy of ASO-mediated NRP1 downregulation." @default.
• W4308378507 created "2022-11-11" @default.
• W4308378507 creator A5000189121 @default.
• W4308378507 creator A5001552182 @default.
• W4308378507 creator A5003527997 @default.
• W4308378507 creator A5013505557 @default.
• W4308378507 creator A5024963052 @default.
• W4308378507 creator A5028798341 @default.
• W4308378507 creator A5044606591 @default.
• W4308378507 creator A5068350308 @default.
• W4308378507 creator A5070871389 @default.
• W4308378507 creator A5085011417 @default.
• W4308378507 creator A5089607652 @default.
• W4308378507 creator A5091717205 @default.
• W4308378507 date "2022-11-01" @default.
• W4308378507 modified "2023-09-30" @default.
• W4308378507 title "434 Targeting the expression of Neuropilin-1 by locked nucleic acid modified antisense oligonucleotides results in potent anti-tumor activity in vivo" @default.
• W4308378507 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0434" @default.
• W4308378507 hasPublicationYear "2022" @default.
• W4308378507 type Work @default.
• W4308378507 citedByCount "0" @default.
• W4308378507 crossrefType "proceedings-article" @default.
• W4308378507 hasAuthorship W4308378507A5000189121 @default.
• W4308378507 hasAuthorship W4308378507A5001552182 @default.
• W4308378507 hasAuthorship W4308378507A5003527997 @default.
• W4308378507 hasAuthorship W4308378507A5013505557 @default.
• W4308378507 hasAuthorship W4308378507A5024963052 @default.
• W4308378507 hasAuthorship W4308378507A5028798341 @default.
• W4308378507 hasAuthorship W4308378507A5044606591 @default.
• W4308378507 hasAuthorship W4308378507A5068350308 @default.
• W4308378507 hasAuthorship W4308378507A5070871389 @default.
• W4308378507 hasAuthorship W4308378507A5085011417 @default.
• W4308378507 hasAuthorship W4308378507A5089607652 @default.
• W4308378507 hasAuthorship W4308378507A5091717205 @default.
• W4308378507 hasBestOaLocation W43083785071 @default.
• W4308378507 hasConcept C104317684 @default.
• W4308378507 hasConcept C127561419 @default.
• W4308378507 hasConcept C129312508 @default.
• W4308378507 hasConcept C150903083 @default.
• W4308378507 hasConcept C153911025 @default.
• W4308378507 hasConcept C167734588 @default.
• W4308378507 hasConcept C173396325 @default.
• W4308378507 hasConcept C185592680 @default.
• W4308378507 hasConcept C190283241 @default.
• W4308378507 hasConcept C203014093 @default.
• W4308378507 hasConcept C207001950 @default.
• W4308378507 hasConcept C2777025900 @default.
• W4308378507 hasConcept C34425596 @default.
• W4308378507 hasConcept C502942594 @default.
• W4308378507 hasConcept C553184892 @default.
• W4308378507 hasConcept C55493867 @default.
• W4308378507 hasConcept C86803240 @default.
• W4308378507 hasConcept C8891405 @default.
• W4308378507 hasConcept C95444343 @default.
• W4308378507 hasConceptScore W4308378507C104317684 @default.
• W4308378507 hasConceptScore W4308378507C127561419 @default.
• W4308378507 hasConceptScore W4308378507C129312508 @default.
• W4308378507 hasConceptScore W4308378507C150903083 @default.
• W4308378507 hasConceptScore W4308378507C153911025 @default.
• W4308378507 hasConceptScore W4308378507C167734588 @default.
• W4308378507 hasConceptScore W4308378507C173396325 @default.
• W4308378507 hasConceptScore W4308378507C185592680 @default.
• W4308378507 hasConceptScore W4308378507C190283241 @default.
• W4308378507 hasConceptScore W4308378507C203014093 @default.
• W4308378507 hasConceptScore W4308378507C207001950 @default.
• W4308378507 hasConceptScore W4308378507C2777025900 @default.
• W4308378507 hasConceptScore W4308378507C34425596 @default.
• W4308378507 hasConceptScore W4308378507C502942594 @default.
• W4308378507 hasConceptScore W4308378507C553184892 @default.
• W4308378507 hasConceptScore W4308378507C55493867 @default.
• W4308378507 hasConceptScore W4308378507C86803240 @default.
• W4308378507 hasConceptScore W4308378507C8891405 @default.
• W4308378507 hasConceptScore W4308378507C95444343 @default.
• W4308378507 hasLocation W43083785071 @default.
• W4308378507 hasOpenAccess W4308378507 @default.
• W4308378507 hasPrimaryLocation W43083785071 @default.
• W4308378507 hasRelatedWork W2024344351 @default.
• W4308378507 hasRelatedWork W2346343701 @default.
• W4308378507 hasRelatedWork W2494327966 @default.
• W4308378507 hasRelatedWork W3021417149 @default.
• W4308378507 hasRelatedWork W3204273758 @default.
• W4308378507 hasRelatedWork W3215845635 @default.
• W4308378507 hasRelatedWork W4220866825 @default.
• W4308378507 hasRelatedWork W4281477203 @default.
• W4308378507 hasRelatedWork W4281778281 @default.
• W4308378507 hasRelatedWork W4311271618 @default.
• W4308378507 isParatext "false" @default.
• W4308378507 isRetracted "false" @default.
• W4308378507 workType "article" @default.